Literature DB >> 8566577

Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis.

T A Brentnall1, R C Haggitt, P S Rabinovitch, M B Kimmey, M P Bronner, D S Levine, K V Kowdley, A C Stevens, D A Crispin, M Emond, C E Rubin.   

Abstract

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) has been suggested as a risk factor for the development of colorectal cancer in ulcerative colitis (UC); however, previous studies of this association have been limited by small numbers of patients with PSC or have been performed retrospectively. This study prospectively evaluates the risk and natural history of colonic tumorigenesis in patients with PSC and UC and compares it with patients with UC without PSC.
METHODS: Twenty patients with PSC and UC and 25 control patients with UC were followed prospectively by colonoscopic surveillance using extensive mucosal biopsy sampling. All control patients with UC had disease extending beyond the sigmoid colon of > or = 8 years' duration; patients with PSC and UC were studied regardless of disease duration.
RESULTS: Forty-five percent (9 of 20) of the patients with PSC and UC had dysplasia compared with 16% (4 of 25) of the control patients with UC (P < or = 0.002). Prior liver transplantation did not affect the risk of colonic dysplasia. The time course for progression to dysplasia was similar between the patients with PSC and UC and the patients with UC; however, the patients with PSC and UC were five times more likely to develop dysplasia.
CONCLUSIONS: Patients with PSC and UC represent a subset of patients with UC who are at markedly increased risk for colonic neoplasia and who need close colonoscopic surveillance with extensive biopsy sampling.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566577     DOI: 10.1053/gast.1996.v110.pm8566577

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  61 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Ulcerative colitis.

Authors:  S Ghosh; A Shand; A Ferguson
Journal:  BMJ       Date:  2000-04-22

Review 3.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 4.  The management of primary sclerosing cholangitis.

Authors:  Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2003-02

5.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Simultaneous detection of synchronous colonic and biliary carcinoma by abdominal ultrasonography in two patients with ulcerative colitis.

Authors:  R D Klingenberg-Noftz; N Homann; I Bos; H P Bruch; D Ludwig
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 7.  The approach to dysplasia surveillance in inflammatory bowel disease.

Authors:  Remo Panaccione
Journal:  Can J Gastroenterol       Date:  2006-04       Impact factor: 3.522

Review 8.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part 1.

Authors:  Sharad Sharma; Ahmet Gurakar; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2007-11-09       Impact factor: 3.199

9.  Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Harry Sokol; Jacques Cosnes; Olivier Chazouilleres; Laurent Beaugerie; Emmanuel Tiret; Raoul Poupon; Philippe Seksik
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 10.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.